# Study of Safety and Immunogenicity of BVRS-GamVac-Combi

> **NCT04128059** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 268 (estimated)

## Conditions studied

- MERS (Middle East Respiratory Syndrome)
- MERS

## Interventions

- **DRUG:** BVRS-GamVac-Combi
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04128059
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-06
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2021-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04128059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04128059, "Study of Safety and Immunogenicity of BVRS-GamVac-Combi". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04128059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*